Unknown

Dataset Information

Exenatide and the treatment of patients with Parkinson's disease.


ABSTRACT:

Unlabelled

BACKGROUND. There is increasing interest in methods to more rapidly and cost-efficiently investigate drugs that are approved for clinical use in the treatment of another condition. Exenatide is a type 2 diabetes treatment that has been shown to have neuroprotective/neurorestorative properties in preclinical models of neurodegeneration. METHODS. As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls. Their PD was compared after overnight withdrawal of conventional PD medication using blinded video assessment of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

SUBMITTER: Aviles-Olmos I 

PROVIDER: S-EPMC3668846 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature